Bladder Cancer COE

BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson

Details
Sam Chang speaks with Mark Tyson about the BOND-003 trial's findings on cretostimogene grenadenorepvec for treating BCG unresponsive carcinoma in situ of the bladder. Dr. Tyson explains the dual-action mechanism of the drug, combining direct tumor cell destruction with enhanced immune response activation. Impressively, the trial shows a 75.2% complete response rate at various time points with a ti...

VA BRAVO 2 Study: Blue Light Cystoscopy Improves Outcomes in NMIBC Patients in Equal Access Setting - Stephen B Williams

Details
Ashish Kamat introduces Stephen B. Williams who discusses findings from his study on blue light cystoscopy in bladder cancer treatment, conducted within the VA healthcare system. The study utilized a propensity score-matched analysis to compare the outcomes of blue light versus white light cystoscopy, focusing on bladder cancer recurrence, progression, and overall survival. The analysis revealed s...

SunRISe-3 Trial: TAR-200 with or without Cetrelimab vs. BCG for BCG-Naive High-Risk NMIBC - Sam Chang

Details
Ashish Kamat hosts Sam Chang to discuss the SunRISe-3 trial. Dr. Chang presents the ongoing trial investigating the efficacy of TAR-200, either alone or combined with cetrelimab, against BCG in treating patients with BCG-naive bladder cancer. TAR-200, a targeted release system using gemcitabine, is tested for its potential benefits over traditional treatments due to its unique delivery system aime...

Racial Differences in Bladder Cancer Detection Using Blue Light Cystoscopy: A Multi-Center Study - Siamak Daneshmand

Details
Ashish Kamat welcomes Siamak (Sia) Daneshmand to discuss the nuances of blue light cystoscopy and its effectiveness across different racial groups. Dr. Daneshmand discusses his team’s research into racial differences in tumor detection rates using blue light cystoscopy. He highlights the study's analysis of detection sensitivity across different races, revealing that while blue light enhances tumo...

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein

Details
Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association's (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in partnership with the Society for Urologic Oncology, these evidence-based guidelines highlight key changes from the 2016 and 2017 versions. The updates include the management of variant histologies, re...

Patient-Driven Outcomes in the CISTO Trial for High-Grade Non-Muscle Invasive Bladder Cancer - Angela Smith & John Gore

Details
Sam Chang introduces a dialogue with John Gore and Angie Smith, who are leading a trial named CISTO, aimed at addressing treatment decisions in non-muscle invasive bladder cancer. The trial compares the efficacy of intravesical therapy and surgery in patients with recurrent bladder cancer who have previously undergone BCG treatment. Emphasizing a pragmatic approach, the trial notably includes phys...

Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis

Details
Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November 2023....

How Long is Recovery After TURBT? Patient-Reported Outcomes Provide Answers - Marshall Strother

Details
Ruchika Talwar hosts Marshall Strother for a discussion on the recovery timeline following TURBT for bladder cancer. Utilizing ecological momentary assessment, Dr. Strother's study tracks patient symptoms and recovery in real-time through daily text-based surveys, offering a detailed view of the recovery process. Findings reveal most patients experience mild symptoms post-surgery, with a significa...

Clearing the Smoke: Underreporting of Smoking Status in Bladder Cancer Clinical Trials - Hannah Kay & Marc Bjurlin

Details
Ruchika Talwar hosts Hannah Kay and Marc Bjurlin to unravel their study on the sparse reporting of smoking status in bladder cancer trials. Their research, "Clearing the Smoke," highlights a concerning discrepancy: only 41.2% of bladder cancer trials over the past decade reported participants' smoking status, starkly contrasting with higher reporting rates in lung cancer trials. This gap suggests...

AIM High: Epigenetic Modulation and Immune Stimulation in Bladder Cancer - Elizabeth Koehne

Details
Sam Chang engages in an conversation with Elizabeth Koehne who delves into her research, AIM HIGH: DNA Methyltransferase Inhibition and Immune Stimulation in Bladder Cancer. The project explores the potential of making bladder cancer more susceptible to immunotherapy by reversing epigenetic mechanisms, like DNA methylation and chromatin remodeling, that the cancer uses to evade the immune system....